Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.
Related Research units
Abstract
To evaluate efficacy and safety of epirubicin and cyclophosphamide followed by paclitaxel and trastuzumab as neoadjuvant treatment in patients with human epidermal growth factor receptor 2 (HER2)-overexpressing breast cancer.
Bibliographical data
| Original language | English |
|---|---|
| Article number | 25 |
| ISSN | 0732-183X |
| Publication status | Published - 2011 |
| pubmed | 21788566 |
|---|
